No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran

Clinical Pharmacokinetics

Volumn 42, Issue 5, 2003, Pages 485-492

  Sarich, Troy C ^a   Teng, Renli ^a   Peters, Gary R ^a   Wollbratt, Maria ^b   Homolka, Robert ^a   Svensson, Mia ^b   Eriksson, Ulf G ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ETHYLMELAGATRAN; MELAGATRAN; MELAGATRAN HYDROXYAMIDINE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; OBESITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; AZETIDINES; BENZYLAMINES; FEMALE; GLYCINE; HALF-LIFE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; OBESITY; THROMBIN;

EID: 0037512328     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342050-00006     Document Type: Article

References (20)

1. Nordström M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep-vein thrombosis with a defined urban population. J Intern Med 1992; 232: 155-60
2. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism, The Worcester DVT study. Arch Intern Med 1991; 151: 933-8
3. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors, a focus on venous thrombosis. Thromb Haemost 1997; 78: 1-6
4. Fenton JW, Ofosu FA, Brezniak DV, et al. Thrombin and antithrombotics. Semin Thromb Hemost 1998; 24: 87-91
5. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8
6. Gustafsson D, Nyström J-E, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81
7. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharm. In press
8. Eriksson UG, Bredberg U, Hoffman K-J, et al. Absorption, distribution, metabolism and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003; 31: 294-305
9. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215-21
10. Francis CW, Davidson BL, Berkowitz SD, et al. A randomized, double-blind, comparative study of ximelagatran and warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 2002; 137: 648-55
11. Eriksson BI, Lindbratt S, Kälebo P, et al. A randomised, controlled study of the oral direct thrombin inhibitor ximelagatran and its active form, melagatran, compared with dalteparin as thromboprophylaxis after total hip or total knee replacement: METHRO II. Lancet 2002; 360: 1441-7
12. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003; 89 (2): 288-96
13. Eriksson H, Wåhlander K, Gustafsson D, et al. A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemostasis 2003; 1: 41-7
14. Petersen P, SPORTIF II and IV Investigators. A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation [abstract 2953]. Blood 2001; 98 Suppl. 1: 706a
15. Seidell JC. Time trends in obesity: an epidemiological perspective. Horm Metab Res 1997; 29: 155-8
16. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-31
17. Sanderink G-J, Liboux AL, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharm Ther 2002; 72: 308-18
18. Larsson M, Logren U, Ahnoff M, et al. Determination of melagatran, a novel direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2002; 766: 47-55
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
20. Eriksson UG, Mandema JW, Karlsson MO, et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clin Pharmacokinet. In press